
Sign up to save your podcasts
Or


340B Insight wants to make our podcast the best it can be. To help us succeed, we’d like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.
This week, we are joined by Steven Miller, vice president of pharmacy services at 340B Health. April 1 was the third anniversary of the federal 340B ceiling price website’s launch. Steve discusses how this database has become an invaluable tool for 340B drug pricing transparency. Before the interview, our news update shares how HRSA escalated enforcement actions against one of the companies restricting 340B discounts. The update also notes the release of 340B Health’s 2021 annual survey report on how hospitals are using their savings.
How the Ceiling Price Website Operates
The drug price database requires drug companies to submit pricing information to HRSA that is then used to calculate 340B ceiling prices for each eligible drug. This makes the website the source of truth. Steve explains who can access the website, the data elements that drug companies submit to HRSA, and the timeline for this process. He also shares the types of analysis that hospitals can do using the ceiling price information.
What to Do When Your Hospital Is Overcharged
Steve recommends how often an authorized official or primary contact at a hospital should check the ceiling price website and what to do if they believe the hospital has been overcharged. Filing overcharge reports are critical to keeping drug companies accountable.
The Impact of the Ceiling Price Website
In its three years, the ceiling price website has increased 340B drug pricing transparency. Steve recaps the trends in recent years’ overcharge reports and HRSA audits of drug companies, estimates how much covered entities are overcharged, and shares examples of how the database has become essential for drug manufacturer accountability and the protection of covered entities’ 340B savings.
Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you’d like us to cover in this podcast, email us at [email protected].
Resources
By 340B Health4.9
2323 ratings
340B Insight wants to make our podcast the best it can be. To help us succeed, we’d like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.
This week, we are joined by Steven Miller, vice president of pharmacy services at 340B Health. April 1 was the third anniversary of the federal 340B ceiling price website’s launch. Steve discusses how this database has become an invaluable tool for 340B drug pricing transparency. Before the interview, our news update shares how HRSA escalated enforcement actions against one of the companies restricting 340B discounts. The update also notes the release of 340B Health’s 2021 annual survey report on how hospitals are using their savings.
How the Ceiling Price Website Operates
The drug price database requires drug companies to submit pricing information to HRSA that is then used to calculate 340B ceiling prices for each eligible drug. This makes the website the source of truth. Steve explains who can access the website, the data elements that drug companies submit to HRSA, and the timeline for this process. He also shares the types of analysis that hospitals can do using the ceiling price information.
What to Do When Your Hospital Is Overcharged
Steve recommends how often an authorized official or primary contact at a hospital should check the ceiling price website and what to do if they believe the hospital has been overcharged. Filing overcharge reports are critical to keeping drug companies accountable.
The Impact of the Ceiling Price Website
In its three years, the ceiling price website has increased 340B drug pricing transparency. Steve recaps the trends in recent years’ overcharge reports and HRSA audits of drug companies, estimates how much covered entities are overcharged, and shares examples of how the database has become essential for drug manufacturer accountability and the protection of covered entities’ 340B savings.
Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you’d like us to cover in this podcast, email us at [email protected].
Resources

4,357 Listeners

5,475 Listeners

499 Listeners

9,202 Listeners

6,072 Listeners

812 Listeners

8,177 Listeners

3,404 Listeners

334 Listeners

190 Listeners

32 Listeners

7 Listeners

4 Listeners

7 Listeners

0 Listeners